Research Professor CNRS
Campus Jourdan – 48 Boulevard Jourdan 75014 Paris
3rd floor, office 59
Phone +33(0)1 80 52 19 08
- Behavioral economics
- Health Systems
- Social protection
- Researcher at CNRS (French National Centre for Scientific Research) since 2002 – Chercheur CNRS (Centre National de recherche Scientifique) depuis 2002
- Vice-President of the scientific council of the Technical Agency for Hospital Information and Reimbursment System (ATIH), nominated as Qualified Members – Président adjointe du conseil scientique de l’Agence technique de l’information sur l’hospitalisation (ATIH) au titre de « personnalité qualifiée »
- Member of administrative database access committee (INSEE) - Membre du comité du secret pour l'accès aux données administratives - INSEE
- Member de scientific committee selection of the Fulbright Scholar Program (Franco-American Commission) – Membre du comité de sélection du Programme Fulbright (commission Franco-américaine)
- 2020 _ External advisor for the High council of the Health Public Insurance (HCAAM) – Conseiller externe pour le Haut conseil pour l'Avenir de l'Assurance maladie (HCAAM)
Hospital (In)efficiency, Healthcare system and Socio-economic Inequality
Controlling hospital expenditures and improving healthcare quality seem irreconcilable. Depending on healthcare regulation, the incentive can be on cost reduction at the expense of quality or the other way around. Therefore, finding the right balance between the two is a most important issue in many developed or developing countries. A fixed-based payment, often associated to a competition mechanism, is the most popular and widely used reimbursement payment over the world. In a context of a private healthcare sector, it raises some issues as patient's selection, innovation adoptions, up-coding, ... this has been widely studied in the US context. But, what can we say in the context of a public healthcare sector? I focused on the T2A (tarification à l'activité) and its consequences: improvement in efficiency, level of quality, suppliers’ behaviour including up-coding, cost regulation. My recent research focuses on bundle payment and the impact of the shift to ambulatory care.
Healthcare Reforms in China and Digital Healthcare
In this field of study, I present a global picture of the healthcare organization including the medication market in China, how public healthcare insurance plans have been implemented over the last years and I study the inefficiency of the Chinese healthcare system and the series of current reforms to deal with. I also expose the increase in the violence in the relationship between patient's relatives and the medical staff, and how the digital healthcare is used as a tool to solve the inefficiency from the public sector and a tool to generate profit by the private sector. Besides, I also focus on healthcare access and urbanization in China, migration and healthcare in China.
Insurance System and Healthcare: Woman's delivery and New-born as a study case
The goal of this research axis is to determine to what extent the presence of health insurance create price distortion on i) the market of drugs, ii) patient's healthcare-seeking behaviour. This question is all the more interesting that the share of drugs in overall health expenditures is steadily growing. The players of the drug industry being global, this issue does not have borders. It is studied in different countries. The focus is also on the healthcare demand itself. To assess this demand, I use both objective measurements (body mass index, mortality rate….) and subjective index (assessment of their own health situation by patients). My studies focused on woman's delivery and new-born as a study case.